AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03806179
Drug: 10 MBq/kg Betalutin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 MBq/kg Betalutin, lilotomab 40mg, rituximab 375 mg/m2
Trial: NCT03806179
Drug: 15 MBq/kg Betalutin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 MBq/kg Betalutin, lilotomab 40mg, rituximab 375 mg/m2
Trial: NCT02076321
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: acetaminophen for pain control with dose and frequency of 10-15mg/kg/dose, Maximum dose 1000mg. Maximum amount per day: 75mg/kg (not to exceed 4g/day).
Trial: NCT02076321
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: ibuprofen for pain control with dose and frequency 4-10mg/kg/dose. Maximum of 40mg/kg/day, not to exceed 3,200mg/day. Maximum one-time dose of 800mg.
Trial: NCT01153763
Drug: GSK2118436
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive 150 mg of GSK2118436 twice daily and continue on treatment until disease progression, death, or unacceptable adverse event.
Trial: NCT04263337
Drug: [11C] PiB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Per study protocol static PET images will be acquired after IV infusion of CPiB to generate standard uptake values (SUVs). PET imaging is necessary in order to address the primary and secondary outcome measures as a component of neurological health (i.e., presence of proteinopathies empirically associated with neurodegenerative disease, cognitive decline, and neurological signs/symptoms). All groups will participate in this portion of the protocol.
Trial: NCT04263337
Drug: [18F] PBR111
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Per study protocol static PET images will be acquired after IV infusion of F-PBR111 to generate standard uptake values (SUVs). PET imaging is necessary in order to address the primary and secondary outcome measures as a component of neurological health (i.e., presence of proteinopathies empirically associated with neurodegenerative disease, cognitive decline, and neurological signs/symptoms). All groups will participate in this portion of the protocol.
Trial: NCT02925104
Drug: INC280
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01858272
Drug: H5.020CMV.PDGF-b and limb compression bandage
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03864016
Drug: Induction and maintenance of anesthesia
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The hypnotic agent used is Propofol and the morphine agent used is Sufentanil.
Trial: NCT03864016
Drug: Adaptation of sufentanil doses according to the usual protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: At induction the target concentration of sufentanil is 0.5 ng/ml. The sufentanil dose is decided by the anaesthetist, taking into account the operating times (induction, TIO, incision, opening and sternal spacing, CEC, closure), the usual data provided by the monitoring: heart rate, blood pressure, BIS, EtCO2, modification of insufflation pressures.
Trial: NCT03864016
Drug: Adjustment of sufentanil doses according to pupillometry
FDA approved: no
EMA approved: no
PMDA approved: no
Description: At induction, the target concentration of sufentanil is 0.5 ng/ml. The dose of sufentanil is then adjusted according to the dilation reflex obtained with the PPI (Pain Pupillary Index) at predefined times.
Trial: NCT04081597
Drug: Star-101
RxNorm normalized name: STAR FRUIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT04081597
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT03340974
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo daily (60 min IV infusion, prior to SBRT), concurrent with daily fractions of SBRT to assigned dose level
Trial: NCT01474746
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo will be dosed in an age-dependent manner. Participants aged 2-3 years of age will be given 2.5 mg (0.125 mL) of liquid placebo once per day for a period of six months. Participants aged 4 years to 5 years 8 months will be given 5 mg (0.25 mL) of liquid placebo once per day for a period of six months.
Trial: NCT03758716
Drug: FB825, FB825-15D11, Anti-CemX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: 20mg/ml solution Route of administration: IV
Trial: NCT00633347
Drug: Antagonist GnRH Cetrotide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetrotide 0.25 mg. daily/ 7 days
Trial: NCT01851330
Drug: LDV/SOF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LDV 90 mg/SOF 400 mg FDC tablet administered orally once daily
Trial: NCT00516152
Drug: Busulfan/Fludarabine phosphate/Tacrolimus/Methotrexate/G-CSF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Day Preparative Regimen for GVHD Prophylaxis~* 7 Busulfan 0.8 mg/kg IV Q6 hurs, Fludarabine 30 mg/m(2)IV~* 6 Busulfan 0.8 mg/kg IV Q6 hurs, Fludarabine 30 mg/m(2)IV~* 5 Busulfan 0.8 mg/kg IV Q6 hurs, Fludarabine 30 mg/m(2)IV~* 4 Busulfan 0.8 mg/kg IV Q6 hurs, Fludarabine 30 mg/m(2)IV~* 3 Fludarabine 30 mg/m(2)IV~* 2 REST Tacrolimus 0.01 mg/kg CIVI~* 1 REST 0 Unrelated Stem Cell/Bone Marrow Infusion~  * 1 Methotrexate 5mg/m(2)IV~ * 3 Methotrexate 5mg/m(2)IV~ * 6 Methotrexate 5mg/m(2)IV~ * 7 G-CSF 5mcg/kg SQ daily~ * 11 Methotrexate 5mg/m(2)IV~ * 90 Evaluate Response
Trial: NCT03412799
Drug: SBP-101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as subcutaneous (SC) injection, escalating dose cohorts
Trial: NCT01420965
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low dose- Immune Enhancer
Trial: NCT03474458
Drug: Doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxycycline
Trial: NCT03474458
Drug: Standard of care therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care therapy
Trial: NCT02303821
Drug: Intrathecal (IT) Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02303821
Drug: Intrathecal Triple Therapy (Intrathecal Cytarabine, Hydrocortisone, and Methotrexate)
RxNorm normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02303821
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01243775
Drug: Belotaxel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg/m2 3 weekly (day 1)
Trial: NCT01243775
Drug: Belloxa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 70 mg/m2 3 weekly (day 2)
Trial: NCT04271917
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactive placebo oil to imitate CBD oil
Trial: NCT04271917
Drug: acetaminophen 500mg and ibuprofen 200mg combo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: standard of care
Trial: NCT04195269
Drug: Test Article
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg CBD, 10 mg of THC, and a proprietary blend of terpenes.
Trial: NCT04428684
Drug: Pepti 3.6 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each patient receives one injection of Pepti 3.6mg or Zoladex 3.6mg on Day 0 and a second injection of the same drug given the first time on Day 28. On Day 42 patients undergo endometrial ablation
Trial: NCT00385008
Drug: Combination Product (sumatriptan succinate / naproxen sodium)
RxNorm normalized name: naproxen sodium / sumatriptan Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sumatriptan/naproxen sodium
Trial: NCT02470845
Drug: placebo patches of placebo-control group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo patch consists of flour and edible pigments. These two ingredients will be mixed with water and made to patches weighted as 2g and 1cm\*1cm round size.Each patch will be applied on one acupoint.
Trial: NCT04032717
Drug: Q-Griffithsin (Q-GRFT) enema
RxNorm normalized name: Chew Q
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigational enema composed of 4.2mL Q-Griffithsin (Q-GRFT) 9.6mg/mL combined with approximately 120.8mL of 0.9% sodium chloride solution to yield an active enema study product that will contain and deliver a dose of approximately 40mg of Q-GRFT
Trial: NCT03266939
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01766336
Drug: Group 1 ELND005
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01766336
Drug: Group 2 ELND005
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04182997
Drug: saline 0.9%
RxNorm normalized name: CVS Saline 0.9% Nasal Mist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients included in the placebo group will have their surgical site lavaged with sterile saline at the end of their surgery.
Trial: NCT04059445
Drug: Biphasic calcium phosphate (Straumann Bone Ceramic) + enamel matrix proteins (Straumann Emdogain)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regenerative therapy with biphasic calcium phosphate + enamel matrix proteins.
Trial: NCT00240630
Drug: sumatriptan succinate/naproxen sodium
RxNorm normalized name: sumatriptan succinate/naproxen sodium 10 mg-60 mg ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination Tablet of Treximet
Trial: NCT00240630
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo to match
Trial: NCT02279433
Drug: DS6051b
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DS-6051b 50 mg and 200 mg capsules for oral administration
Trial: NCT03100123
Drug: Low-molecular-weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The LMWH regime will be at the discretion of the treating physician, with a suggested regime as follows: tinzaparin 4,500 IU sc daily until 20 weeks gestation, and then 4,500 IU sc twice daily until 37 weeks gestation.
Trial: NCT00039702
Drug: [123] 5-I-A-85380
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01128179
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo chewable tablets administered 3 times a day for 12 weeks
Trial: NCT04679493
Drug: XC7 100 mg single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The volunteers will receive a single dose of the ID (1 capsule once, 100 mg)
Trial: NCT04679493
Drug: XC7 200 mg single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The volunteers will receive a single dose of the ID (2 capsules once, 100 mg each)
Trial: NCT04679493
Drug: Placebo single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The volunteers will receive a single dose of the ID (1 or 2 capsules once)
Trial: NCT04679493
Drug: XC7 200 mg multiple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The volunteers will receive multiple doses of the ID during 14 days (2 capsules daily, 100 mg each)
Trial: NCT03903211
Drug: [18F]PI-2620
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imaging for evaluating the accumulation of abnormal tau protein in the brain
Trial: NCT02715570
Drug: PC945 - single doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Safety and tolerability of single doses
Trial: NCT02715570
Drug: Placebo - single doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Safety and tolerability of single doses
Trial: NCT02715570
Drug: Placebo - repeat doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Safety and tolerability of repeat doses
Trial: NCT01499446
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo inhaled twice daily (morning and evening) for 28 days
Trial: NCT04335539
Drug: Standard of Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care antibiotics will be selected by the investigator based on the suspected or confirmed pathogen(s) for the infection in accordance with local standards.
Trial: NCT00962039
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be randomly assigned to citalopram or placebo in a parallel groups design for 8 weeks of double-blind treatment beginning with 10 mg per day week 1, 20 mg per day week 2, and 40 mg per day week 4 or thereafter if response is suboptimal and there are no significant side effects.
Trial: NCT01187108
Drug: Placebo pills
RxNorm normalized name: placebo Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 (or 2 in the placebo group) empty gel capsules
Trial: NCT03352414
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo pill
Trial: NCT01214746
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet Unikalk 1 time pr day for 5 days
Trial: NCT02227329
Drug: Ethanol
RxNorm normalized name: Ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prophylactic ELT will be administered at the time when the HPN is not being infused.
Trial: NCT02227329
Drug: Heparin Lock
RxNorm normalized name: Heparin Lock Flush
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3 mL of 100 U/ml heparin
Trial: NCT02227329
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00234858
Drug: (Hyzaar) losartan/hydrochlorothiazide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50/12.5 mg QD with titration if needed at Week 4 to 100/25 mg QD
Trial: NCT00704509
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Encapsulated tablets, orally, 12 weeks
Trial: NCT00000461
Drug: pravastatin
RxNorm normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00000461
Drug: fatty acids, omega-3
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01388582
Drug: 30 mcg EE and 150 LNG oral contraceptive (Microvlar)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 women will receive oral contraceptive during breastfeeding
Trial: NCT04136353
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 oral tablets twice daily for 96 weeks
Trial: NCT00086281
Drug: Placebo (P)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Oral Solution
Trial: NCT01724086
Drug: TMC647055
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Type=exact number, unit=mg, number=150, form=capsule, route=oral. 3 or 4 capsules of 150 mg will be administered once daily.
Trial: NCT02175901
Drug: Clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: antibiotic of the amoxicillin/clarithromycin-based quadruple therapy
Trial: NCT03502434
Drug: SM04755
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Healthcare professional-applied patches to subjects during the Induction Period on Days 1, 3, 5, 8, 10, 12, 15, 17 and 19, and during the Challenge Period on Day 36. Patches are to be worn by the subject for approximately 48-72 hours before removal and reaction grading.
Trial: NCT02645058
Drug: Intravenous pain medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: If required by the patient
Trial: NCT02117167
Drug: AZD2014
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Target: m-TOR
Trial: NCT02117167
Drug: AZD4547
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Target: FGFR
Trial: NCT02117167
Drug: AZD5363
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Target: AKT
Trial: NCT02117167
Drug: AZD8931
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Target: HER2, EGFR
Trial: NCT02117167
Drug: Standard maintenance for squamous NSCLC
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00437606
Drug: Ethanol
RxNorm normalized name: Ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40g po
Trial: NCT01096849
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02850185
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bronchodilator (LABA,LAMA) with or without ICS.Conventional treatment is invariable with which was given to COPD patients in 3 months before the study.
Trial: NCT04194645
Drug: Placebo tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet
Trial: NCT04194645
Drug: Placebo solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo solution
Trial: NCT02771470
Drug: Probiotics
RxNorm normalized name: probiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microbial composition using probiotic
Trial: NCT02771470
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microbiota modulation using placebo
Trial: NCT02793505
Drug: any drug not known as a major teratogen or major fetotoxicant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is not an intervention but an observed exposure.
Trial: NCT01716975
Drug: EVP-6124
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arms 1, 2
Trial: NCT01716975
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arm 3
Trial: NCT00751556
Drug: Naproxen Sodium 660mg
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Extended release Naproxen Sodium (660mg) administered once a day
Trial: NCT00751556
Drug: Commercial Aleve 220 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate release commercial Aleve (220 mg) administered in a 2 (440 mg) plus one (220 mg) dosing schedule, 660 mg total
Trial: NCT01130597
Drug: spironolactone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03571334
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study participants will total volume 2.5mL of 0.9% Normal saline injected into each limb, max 2 limbs per subject (either bilateral hands or bilateral feet.) Study participants will receive one series of injections during the trial. In the hands, 0.9% Normal saline will be injected across the palmar surface of the digits in a grid like pattern covering a total of 25 sites per limb (0.1mL/site). In the feet, 0.9% Normal saline will be injected across the dorsal surface of the foot in a grid like pattern covering a total of 25 sites per limb (0.1mL/site). Injections will be performed intradermally using a 5/16-inch, 32-g needle
Trial: NCT04335266
Drug: SHR2554
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR2554
Trial: NCT02088684
Drug: LEE011
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LEE011: supplied as capsules of dosage strength of 50 mg or 200 mg. The capsules will be differentiated through different sizes
Trial: NCT02088684
Drug: BYL719
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BYL719: supplied as tablets of dosage strength of 10 mg, 50 mg or 200 mg. Tablets will be differentiated through different sizes and/or colors.
Trial: NCT02088684
Drug: BKM120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BKM120: supplied as 10 mg or 50 mg capsules. The capsules will be differentiated through different sizes.
Trial: NCT02074579
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo given 5g three times daily orally for 4 consecutive weeks
Trial: NCT00123851
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01072539
Drug: tigecycline
RxNorm normalized name: Tigecycline
DrugBank: Tigecycline (DB00560)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: As prescribed by physician in usual clinical practice
Trial: NCT02474667
Drug: ANG-3777
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02317406
Drug: Biostime probiotics sachet children's formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biostime probiotics sachet children's formula,1.5g Oral Single dose
Trial: NCT04527354
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive Placebo once a day during 4 weeks
Trial: NCT01738451
Drug: GSK2118436 75 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each capsule contains 75 mg of GSK2118436A as the mesylate salt, micronized particles as active equivalents.
Trial: NCT03571620
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle Control
Trial: NCT01738451
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo capsules will be administered in Part 2 of the study.
Trial: NCT01546454
Drug: Ethinyl Estradiol-Levonorgestrel combination
RxNorm normalized name: ethinyl estradiol / levonorgestrel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.03 mg ethinyl estradiol, 0.15 mg levonorgestrel oral daily for 21 days
Trial: NCT01546454
Drug: Estradiol
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.05 to 0.3 mg transdermal daily for 26 days
Trial: NCT00952731
Drug: oral placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo taken daily for 4-10 weeks.
Trial: NCT00952731
Drug: placebo gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo gel applied to breasts daily for 4-10 weeks.
Trial: NCT02167854
Drug: BYL719
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02167854
Drug: LJM716
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02682927
Drug: Matching Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo solution for ZX008. The product is sugar free and is intended to be compatible with a ketogenic diet.